A composite image shows the Tino Rangatiratanga flag outside the NZ parliament
Image: The Spinoff

The BulletinApril 7, 2025

Treaty Principles Bill enters its death throes

A composite image shows the Tino Rangatiratanga flag outside the NZ parliament
Image: The Spinoff

A record-breaking consultation process ends with the select committee recommending the Treaty Principles Bill be scrapped – and Act claiming victory anyway, writes Catherine McGregor in today’s extract from The Bulletin.

To receive The Bulletin in full each weekday, sign up here.

Recommended for the bin

It was always going to be a bumpy ride, but few expected the Treaty Principles Bill to detonate quite so spectacularly. On Friday, the justice select committee recommended the bill not proceed – unsurprising, given its near-total rejection in the 300,000-plus submissions received. Of those, 90% opposed the bill, just 8% supported it, and the rest were on the fence. Submitters ranged from school students to the New Zealand Law Society and a phalanx of 50 King’s Counsel, reports Liam Rātana in The Spinoff.

Former PM Jenny Shipley called the bill “reckless” and warned it could lead to “civil war”; Dame Anne Salmond said the process was “dishonest”; Te Pāti Māori described it as a “campaign of misinformation and division”. The select committee held 79 hours of oral hearings across five intense weeks. As the crowds at November’s Hīkoi mō te Tiriti demonstrated, opposition to the bill was not only intellectual or legal, but widespread and deeply personal.

A reversal on the record

Last week, at the eleventh hour, a new controversy appeared in the near-exclusion of tens of thousands of submissions from the official record. The committee had wrapped up its work a month before the deadline, despite the record-breaking volume of submissions – an “appalling lack of process” according to Labour’s Duncan Webb. In the end, a late motion from Act’s Todd Stephenson ensured all submissions could still be tabled. As clerk of the House David Wilson tells RNZ’s Phil Smith, under normal rules, once a committee has reported a bill to the House, its work is over and it is unable to add anything more to the bill. The change means the committee “can continue to deal with [the submissions] as if it still had the bill” though they won’t be part of the report. Instead they’ll be added to the permanent archive, a move welcomed across party lines.

Second reading looms

Despite the recommendation to scrap it, the bill will still receive its second reading – possibly as soon as this week – thanks to the National-Act coalition agreement. It will almost certainly be voted down, but not before another round of speeches in the House. The NZ Herald’s Thomas Coughlan argues it’s time for the PM to front, given it’s been a “long time since we heard a Prime Minister deliver a speech of substance on Crown-Māori, summing up where the country has been and where it is going”. Luxon’s silence on the bill is in keeping with parliamentary precedent, but Coughlan makes the case that this is no ordinary bill. “Now is the time for such a speech – if not in the debate itself, then perhaps soon after the bill is dispatched.” Especially, he notes, as Luxon owes his premiership to the compromise that let it come this far.

‘If you regularly enjoy The Spinoff, and want it to continue, become a member today.’
Toby Manhire
— Editor-at-large

A political loss – or a strategic win?

No legislation means no treaty principles referendum – at least not this time. But Act leader David Seymour remains undeterred, arguing that “New Zealanders are ready to have this discussion”. Joel Maxwell, writing in Stuff, isn’t so sure the tide of opposition to the bill tells the full story. Public polling has shown a more nuanced picture, with a large chunk of the electorate unsure where they stand.

While most political parties have firmly rejected the bill, Act has gained something else: visibility and momentum. “Even as it gets the stink-eye from its coalition partners… Act can probably feel that even if it has not yet achieved its current goal in politics, it has succeeded politically,” Maxwell concludes. The bill may be headed for the legislative scrapheap, but the argument it sparked isn’t going away.

Keep going!
Boxes of Wegovy and Ozempic injections are displayed against an orange background. The packaging shows dosages and instructions for semaglutide, a medication used for diabetes and weight management. The side banner reads "The Bulletin.
Ozempic and Wegovy, two popular drugs made available in New Zealand years after they were first approved overseas. (Image: Getty / The Spinoff)

The BulletinApril 3, 2025

‘Rule of two’ set to end Medsafe’s sluggish approval process

Boxes of Wegovy and Ozempic injections are displayed against an orange background. The packaging shows dosages and instructions for semaglutide, a medication used for diabetes and weight management. The side banner reads "The Bulletin.
Ozempic and Wegovy, two popular drugs made available in New Zealand years after they were first approved overseas. (Image: Getty / The Spinoff)

The government is scheduled to announce reforms to fast-track new drugs based on prior overseas approvals, writes Catherine McGregor in today’s extract from The Bulletin.

To receive The Bulletin in full each weekday, sign up here.

Quicker drug approvals on their way

The government is expected to unveil reforms today that will allow faster approval of medicines already in use overseas, delivering on a promise in the National-Act coalition agreement. The new regime enables the health minister to sign off new drugs if they’ve received full approval from at least two of seven designated regulators, including agencies in the US, UK, Australia, Canada and the EU. While the coalition agreement pledged that Medsafe must approve such drugs within 30 days, that specific deadline hasn’t made it into the legislation – though associate health minister David Seymour is expected to commit to it in practice, reports Marc Daalder in Newsroom.

One notable change: the legislation’s regulatory impact statement had “envisaged Medsafe making the final decisions to approve, reject or transfer applications under the new pathway”, Daalder writes. “Instead, the bill as written would give that power to the health minister, after the Director-General of Health ensured the application met the basic requirements for streamlining.”

New Zealand ‘at the back of the queue’ for new drugs

For years, critics have called New Zealand’s medicines approval process frustratingly sluggish, and sometimes dangerously so. Medsafe’s years-delayed approval of the mpox vaccine during a global outbreak is just one recent example. The Covid-19 vaccine rollout faced similar delays, with Medsafe slower than overseas counterparts to approve vaccines already in widespread use – a frustration that helped drive the development of this legislation, Daalder writes.

Around the time of the last election, economist Eric Crampton began advocating for a “rule of two” allowing automatic approval after two approvals by trusted overseas regulators. He has described the current process as actively harmful. “Requiring companies to jump over bespoke New Zealand hurdles … when they’ve already proven themselves fit by jumping more rigorous hurdles overseas, just puts Kiwis at the back of the queue,” he wrote in Newsroom in 2023. In fact, the new legislation closely mirrors the system Crampton recommended in his report ‘Safe to Follow: Faster Access to Medicines for Kiwis’.

‘If you regularly enjoy The Spinoff, and want it to continue, become a member today.’
Toby Manhire
— Editor-at-large

Wegovy: better late than never

This week’s announcement comes hot on the heels of Medsafe finally approving Wegovy, a high-profile semaglutide drug used for weight loss. Wegovy, made by Novo Nordisk, is often described as a “sister drug” to Ozempic, which is approved here for diabetes treatment. The two medications work in similar ways but are prescribed for different purposes. Seymour called Wegovy’s approval “very exciting,” but said it also illustrates why reforms are overdue. “The fact something got consented is not in itself evidence of [Medsafe’s] high performance,” he told reporters. Wegovy had already been approved overseas for years – and had transformed obesity treatment in many countries – by the time it got through New Zealand’s process.

Who can get Wegovy and Ozempic?

The real promise of semaglutide drugs may go far beyond weight loss or diabetes. Research is now exploring their potential in areas as diverse as cardiovascular disease, addiction and even dementia. Some studies suggest they could help reduce the risk of stroke or treat fatty liver disease. Yet for now, both Ozempic and Wegovy remain tightly regulated in Aotearoa, as in most countries. Ozempic can be prescribed for type 2 diabetes, while Wegovy – once available – will be restricted to those with a BMI that “classes them as obese, or overweight in the presence of at least one weight-related comorbidity”, reports Jamie Ensor in the Herald.

For patients, that’s a potentially transformative option. For the health system, Seymour argues, it’s a cost-saving opportunity. While noting that he respects Pharmac’s independence, he says he’s asked the agency “to start saying, how can spending more on pharmaceuticals save us money elsewhere? Wegovy and Ozempic may be perfect examples of that.”